Market Place
Sourcing Support
Mesoblast Names Dr. Montagut as Head of Clinical, Medical Affairs
11 Mar 2026 //
GLOBENEWSWIRE
Ryoncil Net Revenues Hit $30M in Quarter
28 Jan 2026 //
GLOBENEWSWIRE
Ryoncil Demonstrates 84% Survival Rate In Children With SR-aGvHD
26 Jan 2026 //
GLOBENEWSWIRE
Ryoncil Sales Increase 60% In December Quarter To US$35.1M
08 Jan 2026 //
GLOBENEWSWIRE
Mesoblast Revamps Board Leadership Roles
01 Jan 2026 //
GLOBENEWSWIRE
Mesoblast Retires Senior Debt via Non-Dilutive Credit Line
29 Dec 2025 //
GLOBENEWSWIRE
Mesoblast to Attend Piper Sandler Conference
03 Dec 2025 //
GLOBENEWSWIRE
James M. O`brien Appointed Chief Financial Officer at Mesoblast
17 Nov 2025 //
GLOBENEWSWIRE
Ryoncil Gets CMS J-Code Enabling Reimbursement, Wider Access
02 Oct 2025 //
GLOBENEWSWIRE
Mesoblast Enters Option to Issue US$50M Convertible Notes
03 Sep 2025 //
GLOBENEWSWIRE
Mesoblast Financial Results and Corporate Update Webcast
27 Aug 2025 //
GLOBENEWSWIRE
Mesoblast Appoints Corporate Finance Leader Lyn Cobley To Board
28 Apr 2025 //
GLOBENEWSWIRE
Mesoblast Expands Ryoncil® Coverage to 100M+ US Lives
16 Apr 2025 //
GLOBENEWSWIRE
First Three Children to Commence Treatment With Ryoncil®
30 Mar 2025 //
GLOBENEWSWIRE
Mesoblast CEO To Deliver Featured Talk At ISCT North America
12 Mar 2025 //
GLOBENEWSWIRE
Mesoblast Prices Ryoncil Based On Economic Value, Q4 Availability
26 Feb 2025 //
GLOBENEWSWIRE
Mesoblast Financial Results and Corporate Update Webcast
25 Feb 2025 //
GLOBENEWSWIRE
Dr. Gregory George MD PhD Joins Mesoblast Board
23 Feb 2025 //
GLOBENEWSWIRE
Ryoncil FDA Approval & Market Launch Highlighted At Tandem Meetings
13 Feb 2025 //
GLOBENEWSWIRE
Appendix 4C Quarterly Activity Report for Quarter Ended Dec 31
30 Jan 2025 //
GLOBENEWSWIRE
Ryoncil Commercial Launch Update and Product Pipeline
30 Jan 2025 //
GLOBENEWSWIRE
Appendix 4C Quarterly Report for Q3 Ended Sept 30, 2024
30 Oct 2024 //
GLOBENEWSWIRE
Mesoblast Option For US$50 Million Convertible Notes for Launch
29 Sep 2024 //
GLOBENEWSWIRE
Mesoblast Financial Results and Corporate Update Webcast
27 Aug 2024 //
GLOBENEWSWIRE
Phase 3 Trial Of Rexlemestrocel-L For Chronic Low Back Pain Begins
21 Jul 2024 //
GLOBENEWSWIRE
Mesoblast Successfully Completes Placement and Accelerated Entitlement Offer
13 Mar 2024 //
GLOBENEWSWIRE
Mesoblast Reports Financial Results for Half-Year Ended December 31, 2023
28 Feb 2024 //
GLOBENEWSWIRE
FDA Grants Mesoblast Rare Pediatric Disease Designation for Revascor
18 Jan 2024 //
GLOBENEWSWIRE
Mesoblast Partners With Blood and Marrow Transplant Clinical Trials Network
21 Nov 2023 //
GLOBENEWSWIRE
Appendix 4C Quarterly Activity Report for Quarter Ended September 30, 2023
30 Oct 2023 //
GLOBENEWSWIRE
Mesoblast Next Steps to Achieve RYONCIL Approval
21 Sep 2023 //
GLOBENEWSWIRE
Mesoblast Director Philip R. Krause, M.D., Appointed to Strategic Advisory Role
04 Jun 2023 //
GLOBENEWSWIRE
Mesoblast Reports Financial Highlights for Quarter Ended March 31, 2023
25 May 2023 //
GLOBENEWSWIRE
Mesoblast Financial Results and Corporate Update Webcast
24 May 2023 //
GLOBENEWSWIRE
Mesoblast Completes Private Placement
25 Apr 2023 //
GLOBENEWSWIRE
Mesoblast soars on U.S. FDA`s nod to review lead drug candidate
08 Mar 2023 //
REUTERS
Remestemcel-L Clinical and Potency Studies Presented at Premier Meeting
16 Feb 2023 //
GLOBENEWSWIRE
FDA Grants Rmat Designation for Rexlemestrocel-L in Chronic Low Back Pain
08 Feb 2023 //
GLOBENEWSWIRE
Appendix 4C Quarterly Activity Report
31 Jan 2023 //
GLOBENEWSWIRE
Mesoblast and Oaktree Extend Availability Period of Undrawn Tranches
22 Dec 2022 //
GLOBENEWSWIRE
Mesoblast sees cell therapy survival data as key to resubmission
23 Nov 2022 //
FIERCEBIOTECH
Mesoblast Reports Financial Results for the Period Ended September 30, 2022
22 Nov 2022 //
GLOBENEWSWIRE
Mesoblast keeps hopes of cell therapy approval alive
03 Oct 2022 //
FIERCEBIOTECH
Mesoblast Submits New Information to FDA IND for SR-aGVHD
02 Oct 2022 //
GLOBENEWSWIRE
Mesoblast Reports Financial Results and Operational Highlights forFY Ended
30 Aug 2022 //
GLOBENEWSWIRE
Jane Bell Joins Mesoblast Board
18 Aug 2022 //
GLOBENEWSWIRE
Rexlemestrocel-L to be Highlighted at Maxim`s Panel on Late-Stage Advancements
11 Jul 2022 //
GLOBENEWSWIRE
Mesoblast Key Opinion Leader Event Series for Investors & Analysts
09 Jun 2022 //
GLOBENEWSWIRE
Philip R. Krause, Former FDA Deputy Chief for Vaccines, Joins Mesoblast Board
23 Mar 2022 //
GLOBENEWSWIRE
Mesoblast Corporate Update and Financial Results Webcast
24 Feb 2022 //
GLOBENEWSWIRE
Rapid Improvement, Remission in Refractory Ulcerative Colitis & Crohn’s Colitis
20 Feb 2022 //
GLOBENEWSWIRE
Mesoblast Appoints Dr. Eric Rose as Chief Medical Officer
01 Feb 2022 //
GLOBENEWSWIRE
Appendix 4C Quarterly Activity Report
30 Jan 2022 //
GLOBENEWSWIRE
Single Dose of Mesoblast Allogeneic Cell Therapy Provides Durable Pain Reduction
11 Jan 2022 //
GLOBENEWSWIRE
Mesoblast Provides Update Following Meeting With FDA’s OTAT on Remestemcel-L
30 Dec 2021 //
GLOBENEWSWIRE
Mesoblast shares depressed by Novartis deal termination
15 Dec 2021 //
BIOWORLD
Novartis Drops Out of COVID-19 Deal with Mesoblast
15 Dec 2021 //
BIOSPACE
Mesoblast and Oaktree Capital Enter Into Refinancing and Expansion
20 Nov 2021 //
GLOBENEWSWIRE
Mesoblast Announces Late Breaking Presentation at American Heart Association
15 Nov 2021 //
TRIALSITENEWS
Late Breaking Presentation at AHA of Landmark Ph3 Trial of Rexlemestrocel-L
13 Nov 2021 //
GLOBENEWSWIRE
